Andrew Fein Reiterates Buy Rating on United Therapeutics

Summary

Andrew Fein has given a Buy rating for United Therapeutics, citing favorable legal standing in ongoing patent litigation against Liquidia. Additionally, RBC Capital has initiated coverage with a Buy rating and a $569 price target. Fein is a 5-star analyst with a 16.6% average return and 51.22% success rate in the Healthcare sector.Tip Ranks

Impact Analysis

So basically, Andrew Fein’s Buy rating for United Therapeutics is a significant endorsement, especially considering his strong track record in the healthcare sector. The timing is interesting, given the favorable legal standing in the ongoing patent litigation against Liquidia, which Fein believes will not significantly affect the outcome. This suggests a high level of confidence in United Therapeutics’ legal position and future prospects. Additionally, RBC Capital’s initiation of coverage with a Buy rating and a $569 price target adds another layer of credibility. The market might be underestimating the positive impact of these legal developments and the strong analyst endorsements. Given the technical indicators showing a strong upward trend and the recent price movements, this could be a good entry point for investors looking to capitalize on potential upside.Tip Ranks